Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Melanoma

Study type: Observational

Funder types: Industry

Identifiers

NCT02717364

CA184-438

Details and patient eligibility

About

This study is a local, prospective, non-interventional, non-controlled, multicenter, observational study (regulatory postmarketing surveillance). Each physician will enroll patients who have received at least 1 dose of Yervoy, and each patient will be followed for up to 12 months. All patients will be evaluated for safety and effectiveness during Yervoy use (4 doses) and for 12 months from the first dose of Yervoy to confirm the safety profile of Yervoy under routine, daily practice

Enrollment: 556 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients who are initiating treatment with Yervoy

Exclusion criteria

• Not Applicable

Other protocol defined inclusion/exclusion criteria could apply

Trial design

556 participants in 1 patient group

Population With Yervoy Exposure

Description:

Population With Yervoy Exposure